Multi-component Workplace Energy Balance Intervention



Status:Completed
Conditions:Obesity Weight Loss
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:40 - 64
Updated:5/11/2018
Start Date:June 2016
End Date:May 2018

Use our guide to learn which trials are right for you!

The purpose of the WorkACTIVE-P study is to assess the outcome of an innovative
multi-component intervention focused on increasing energy expenditure and re-balancing the
disrupted energy balance equation of sedentary workplaces with an ultimate target of reducing
workers' abdominal obesity.

The energy expenditure intervention includes replacing workplace sedentary time with access
to a dedicated pedal desk and increasing steps/day with wearable monitors. Both components
are incorporated into an electronically-delivered behavior monitoring and support
infrastructure, thus enabling continuous management. The investigators will utilize
pedaldesks manufactured and owned by Pennington Biomedical Research Center to conduct this
study at Blue Cross Blue Shield of Louisiana offices in Baton Rouge, La. 40 individuals will
be recruited and randomized to either a control arm or combined Walk More Pedal Desk (WMPD)
intervention. Primary (MRI-determined visceral adipose tissue) and secondary (changes in body
weight, total adipose tissue, subcutaneous adipose tissue, blood pressure, blood lipids,
fasting glucose and insulin, HbA1-c, free-living accelerometer-determined walking, time spent
in sedentary behavior, exercise, and dietary intake) outcomes will be assessed at baseline
and month 3.

Inclusion Criteria:

- BMI: > or equal to 25.0 kg/m2 and < or equal to 40 kg/m2

- Waist Circumference: >102 cm (men) or > 88 cm (women)

- Any one of the other four defining risk factors defining metabolic syndrome
(Triglycerides > or equal to 150 mg/dL , HDL Cholesterol < 40 mg/dL (men) or < 50
mg/dL (women), Resting blood pressure > or equal to 130 mm Hg systolic / 85 mm Hg
diastolic, Fasting glucose > or equal to 110 mg/dL)

Exclusion Criteria:

- Systolic blood pressure > 179 mmHg and/or diastolic blood pressure > 99 mmHg

- Self-reported Type 1 or Type 2 diabetes, or use of diabetes-related medications

- Significant CVD or disorders

- Other significant medical conditions including but not limited to implants that may
interfere with MRI, chronic respiratory, gastrointestinal, neuromuscular, or
psychiatric conditions, malignancies in the past 5 years, with the exception of skin
cancer therapeutically controlled, endocrine (including diabetes), any other medical
conditions or disease (including arthritis) that is life threatening or that can
interfere with or be aggravated by exercise.

- Poor compliance to activity monitors
We found this trial at
1
site
6400 Perkins Rd
Baton Rouge, Louisiana 70808
(225) 763-2500
Phone: 225-763-3000
Pennington Biomedical Research Center Unlike other medical research facilities where science occurs in separate labs...
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials